| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1021550274 |
| P356 | DOI | 10.2165/00019053-200422003-00005 |
| P698 | PubMed publication ID | 15669152 |
| P2093 | author name string | Evo Alemao | |
| Michael Drummond | |||
| John R Cook | |||
| Don Yin | |||
| P2860 | cites work | Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. | Q52236262 |
| Cardiovascular disease risk profiles. | Q52461317 | ||
| A model for evaluating the cost-effectiveness of cholesterol-lowering treatment | Q67602792 | ||
| Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model | Q69414455 | ||
| The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease | Q70309305 | ||
| The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering | Q70309308 | ||
| Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study | Q24630111 | ||
| Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) | Q29547825 | ||
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study | Q29617822 | ||
| Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | Q29619842 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin | Q34190482 | ||
| Deaths: leading causes for 2001. | Q34277816 | ||
| Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field | Q35126849 | ||
| The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity | Q41123578 | ||
| The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals | Q41722263 | ||
| Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia | Q44210740 | ||
| Patients' achievement of cholesterol targets: a cross-sectional evaluation | Q44633256 | ||
| Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults | Q44677541 | ||
| Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) | Q44966192 | ||
| Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. | Q50547799 | ||
| Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. | Q51631986 | ||
| Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts | Q52017724 | ||
| Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. | Q52082107 | ||
| Primary and subsequent coronary risk appraisal: new results from the Framingham study. | Q52082530 | ||
| P921 | main subject | hypercholesterolemia | Q762713 |
| P304 | page(s) | 37-48 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia | |
| P478 | volume | 22 Suppl 3 |
| Q51935762 | Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. |
| Q35931525 | Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany |
| Q45237338 | Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway |
| Q37870094 | Cost-effectiveness of statins revisited: lessons learned about the value of innovation |
| Q34801961 | Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia |
| Q28298648 | Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach |
| Q45969902 | Statin prescribing in Northern Ireland and England pre and post introduction of the quality and outcomes framework. |
Search more.